Prot #GLSI-21-01: A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and

Project: Research project

Project Details

StatusActive
Effective start/end date5/31/23 → 5/31/26

Funding

  • Greenwich LifeSciences, Inc. (Prot #GLSI-21-01)